Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057304 · ClinicalTrials.gov registry record · Phase 2
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT00057304 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 190 participants.
The verdict
NCT00057304, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 2 to 5 mg/day will be studied.
Interventions
- DRUG RO 205-2349
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057304
The ClinicalTrials.gov registry entry for NCT00057304 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO 205-2349 is the first listed.
NCT00057304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057304 about?
NCT00057304 is a clinical study titled "Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus". The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 2 to 5 mg/day will be studied.
What is the current status of trial NCT00057304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2003-06. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00057304?
The interventions under investigation include: RO 205-2349 (DRUG).
Who is sponsoring clinical trial NCT00057304?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.